Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US.

"Disclosure KD, SGN, and RP are employees of GSK and hold stock and shares at GSK. MB is a former employee of GSK and holds stocks and shares at GSK. GG, FL, MM, and MSD are employees of Analysis Group, a consulting company that received research funds from GSK to conduct this study but did not receive payment for manuscript development. MSD also reports that Analysis Group has received grants from AbbVie, Apellis, AstraZeneca, Ayala Pharmaceuticals, Bayer, Blueprint Medicines, GSK, Humacyte, Janssen, Merck, Novartis, Pfizer, Sanofi, and Takeda, outside the submitted work. RB is a staff Pulmonary Physician at the National Jewish Health and is on speaker bureaus and advisory boards for GSK, AstraZeneca, Sanofi, Merck, and Regeneron. The authors report no other conflicts of interest in this work."

"This study was funded by GSK (214181)."